53 / 220
head and neck cancer: the utility of PET-CT.
Laryngoscope
.
2007;117:2129-2134.
31. Ng S-H, Chan S-C, Yen T-C, et al. PET/CT and 3-T whole-
body MRI in the detection of malignancy in treated oropharyn-
geal and hypopharyngeal carcinoma.
Eur J Nucl Med Mol
Imaging
. 2011;38:996-1008.
32. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of posi-
tron emission tomography for the detection of disease in resi-
dual neck nodes after (chemo) radiotherapy in head and neck
cancer.
Head Neck
. 2005;27:175-181.
33. Rege S, Maass A, Chaiken L, et al. Use of positron emission
tomography with fluorodeoxyglucose in patients with extracra-
nial head and neck cancers.
Cancer
. 1994;73:3047-3058.
34. Rogers JW, Greven KM, McGuirt WF, et al. Can post–rt neck
dissection be omitted for patients with head-and-neck cancer
who have a negative pet scan after definitive radiation ther-
apy?
Int J Radiat Oncol Biol Phys
. 2004;58:694-697.
35. Sjovall J, Brun E, Almquist H, Kjellen E, Wahlberg P.
Radiotherapy response in head and neck cancer: evaluation of
the primary tumour site.
Acta Otolaryngol
. 2014;134:646-651.
36. Wang YF, Liu RS, Chu PY, et al. Positron emission tomogra-
phy in surveillance of head and neck squamous cell carcinoma
after definitive chemoradiotherapy.
Head Neck
. 2009;31:442-
451.
37. Yen TC, Lin CY, Wang HM, et al. 18F-FDG-PET for evalua-
tion of the response to concurrent chemoradiation therapy with
intensity-modulated radiation technique for Stage T4 nasophar-
yngeal carcinoma.
Int J Radiat Oncol Biol Phys
. 2006;65:
1307-1314.
38. Gupta T, Master Z, Kannan S, et al. Diagnostic performance
of post-treatment FDG PET or FDG PET/CT imaging in head
and neck cancer: a systematic review and meta-analysis.
Eur J
Nucl Med Mol Imaging
. 2011;38:2083-2095.
39. Isles MG, McConkey C, Mehanna HM. A systematic review and
meta-analysis of the role of positron emission tomography in the
follow up of head and neck squamous cell carcinoma following
radiotherapy or chemoradiotherapy.
Clin Otolaryngol
. 2008;33:
210-222.
40. Gao S, Li S, Yang X, Tang Q. 18FDG PET-CT for distant metas-
tases in patients with recurrent head and neck cancer after defini-
tive treatment: a meta-analysis.
Oral Oncol
. 2014;50:163-167.
41. Fakhry N, Lussato D, Jacob T, Giorgi R, Giovanni A, Zanaret M.
Comparison between PET and PET/CT in recurrent head and neck
cancer and clinical implications.
Eur Arch Otorhinolaryngol
. 2007;
264:531-538.
42. Ishikita T, Oriuchi N, Higuchi T, et al. Additional value of
integrated PET/CT over PET alone in the initial staging and
follow up of head and neck malignancy.
Ann Nucl Med
. 2010;
24:77-82.
43. Chan JY, Sanguineti G, Richmon JD, et al. Retrospective
review of positron emission tomography with contrast-
enhanced computed tomography in the posttreatment setting in
human papillomavirus–associated oropharyngeal carcinoma.
Arch Otolaryngol Head Neck Surg
. 2012;138:1040-1046.
44. Halpern BS, Yeom K, Fueger BJ, Lufkin RB, Czernin J,
Allen-Auerbach M. Evaluation of suspected local recurrence
in head and neck cancer: a comparison between PET and PET/
CT for biopsy proven lesions.
Eur J Radiol
. 2007;62:199-204.
45. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic
value of [(18)F]fluorodeoxyglucose positron emission tomo-
graphy for recurrent head and neck squamous cell carcinoma.
J Clin Oncol
. 2002;20:4199-4208.
46. Keyes JW Jr.SUV: standard uptake or silly useless value?
J
Nucl Med
. 1995;36:1836-1839.
47. Lapela M, Eigtved A, Jyrkkio¨ S, et al. Experience in qualita-
tive and quantitative FDG PET in follow-up of patients with
suspected recurrence from head and neck cancer.
Eur J
Cancer
. 2000;36:858-867.
48. Ghanooni R, Delpierre I, Magremanne M, et al. 18F-FDG
PET/CT and MRI in the follow-up of head and neck squamous
cell carcinoma.
Contrast Media Mol Imaging
. 2011;6:260-266.
49. Greven KM, Williams DW, Keyes JW, et al. Positron emission
tomography of patients with head and neck carcinoma before
and after high dose irradiation.
Cancer
. 1994;74:1355-1359.
50. Kim JW, Roh JL, Kim JS, et al. 18F-FDG PET/CT surveil-
lance at 3–6 and 12 months for detection of recurrence and
second primary cancer in patients with head and neck squa-
mous cell carcinoma.
Br J Cancer
. 2013;109:2973-2979.
51. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M,
Pauwels S. Positron emission tomography with fluorodeoxy-
glucose for suspected head and neck tumor recurrence in the
symptomatic patient.
Laryngoscope
. 2000;110:1493-1497.
52. Purohit BS, Ailianou A, Dulguerov N, Becker CD, Ratib O,
Becker M. FDG-PET/CT pitfalls in oncological head and neck
imaging.
Insights Imaging
. 2014;5:585-602.
53. Lango MN, Myers JN, Garden AS. Controversies in surgical
management of the node-positive neck after chemoradiation.
Semin Radiat Oncol
. 2009;19:24-28.
54. Zhou XH. Correcting for verification bias in studies of a diag-
nostic test’s accuracy.
Stat Methods Med Res
. 1998;7:337-353.
Otolaryngology–Head and Neck Surgery 154(3)
33